Skye Bioscience, Inc.
OTC:SKYE
1.74 (USD) • At close November 17, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.34 | 0.016 |
| Cost of Revenue
| 0.124 | 0.115 | 0.034 | 0.002 | 0.001 | 0.002 | 0.008 | 0.015 | 0.01 | 0 | 0.131 | 0.005 |
| Gross Profit
| -0.124 | -0.115 | -0.034 | -0.002 | -0.001 | -0.002 | -0.008 | -0.015 | -0.01 | 0 | 0.209 | 0.011 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.614 | 0.67 |
| Reseach & Development Expenses
| 5.819 | 6.012 | 2.931 | 1.944 | 2.238 | 0.33 | 0.311 | 0.939 | 0.576 | 0.228 | 0 | 0 |
| General & Administrative Expenses
| 7.852 | 6.095 | 4.916 | 4.345 | 4.395 | 4.363 | 3.548 | 3.532 | 3.741 | 2.504 | 0.12 | 0.006 |
| Selling & Marketing Expenses
| -0.124 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 7.728 | 6.095 | 4.916 | 4.345 | 4.395 | 4.363 | 3.548 | 3.532 | 3.741 | 2.504 | 0.12 | 0.006 |
| Other Expenses
| 21.063 | 0 | 0 | 0 | 0 | 0 | 0.103 | -0.049 | -1.004 | 0 | 0.067 | 0 |
| Operating Expenses
| 13.548 | 12.106 | 7.848 | 6.289 | 6.633 | 4.693 | 3.859 | 4.471 | 4.317 | 2.732 | 0.12 | 0.007 |
| Operating Income
| -13.672 | -18.312 | -7.848 | -6.289 | -6.633 | -4.693 | -3.859 | -4.471 | -4.317 | -2.732 | -0.12 | 0.004 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.354 | 0.253 |
| Total Other Income Expenses Net
| -23.969 | -1.163 | -0.672 | -0.27 | 7.686 | -14.268 | 0.767 | 1.294 | -0.522 | 0 | 0.003 | 0.001 |
| Income Before Tax
| -37.641 | -19.475 | -8.52 | -6.559 | 1.053 | -19.193 | -3.093 | -3.176 | -4.839 | -2.732 | -0.004 | 0.005 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.011 | 0.293 |
| Income Tax Expense
| 0.004 | 0.007 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.003 | -0.003 | 0 |
| Net Income
| -37.645 | -19.482 | -8.522 | -6.561 | 1.052 | -19.194 | -3.094 | -3.178 | -4.841 | -2.734 | -0.12 | 0.005 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.354 | 0.278 |
| EPS
| -5.37 | -9.82 | -5.24 | -6.39 | 1.98 | -36.51 | -25.62 | -41.93 | -71.45 | -65.08 | -3.52 | 0.13 |
| EPS Diluted
| -5.37 | -9.82 | -5.15 | -6.39 | 1.98 | -36.51 | -25.62 | -39.9 | -70.93 | -65.08 | -3.52 | 0.13 |
| EBITDA
| -13.548 | -12.093 | -7.815 | -6.287 | -6.644 | -4.828 | -3.748 | -5.798 | -4.789 | -2.73 | -0.12 | 0.005 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.354 | 0.293 |